NICE rejects Sanofi’s Cablivi in draft guidelines
Trial data does not show whether adding Cablivi to standard care improves either length or quality of life over the long term, the Institute said
Read More
Tag: aTTP
Sanofi’s Cablivi cleared for rare bleeding disorder
Patients with the rare clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) have gained a new treatment option in Europe with the approval of Sanofi’s Cablivi.
Read More
Ablynx files caplacizumab for ultra rare blood disorder
Patients in Europe with the ultra rare blood clotting disorder acquired thrombotic thrombocytopenic purpura (aTTP) are a step closer to getting the first therapeutic specifically indicated for treating the disease, after Ablynx filed for approval of caplacizumab.
Read More
- Ipsen announces new data on Dysport in neurological disease
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
